Remission InductionRemission, SpontaneousPlacebo EffectDouble-Blind MethodTreatment OutcomeRecurrenceTime FactorsCytarabineFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleDrug Therapy, CombinationMaintenance ChemotherapyLeukemia, Myeloid, AcuteCross-Over StudiesPrednisoneCombined Modality TherapyCyclophosphamideMaintenanceVincristinePrecursor Cell Lymphoblastic Leukemia-LymphomaPrednisoloneMethotrexateDaunorubicinAdministration, OralPrognosisClinical Trials as TopicDose-Response Relationship, DrugTransplantation, AutologousSeverity of Illness IndexProspective StudiesDisease-Free SurvivalAntirheumatic AgentsImmunosuppressive AgentsAcute DiseaseMesalamineBone Marrow TransplantationColitis, UlcerativeSurvival AnalysisRandomized Controlled Trials as TopicLeukemia, LymphoidLeukemia, MyeloidNephrotic SyndromeGastrointestinal Agents6-MercaptopurineHematopoietic Stem Cell TransplantationAntineoplastic AgentsAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedNeoplasm, ResidualRetrospective StudiesThioguanineCrohn DiseaseTransplantation, HomologousSurvival RateArthritis, RheumatoidDoxorubicinAnti-Inflammatory AgentsBone MarrowAsparaginaseDepressive Disorder, MajorEtoposideLeukemia, Promyelocytic, AcuteLeukemiaGlucocorticoidsInfusions, IntravenousIdarubicinLymphoma, Non-HodgkinSalvage TherapyPilot ProjectsDisease ProgressionAntidepressive AgentsAnti-Inflammatory Agents, Non-SteroidalAminosalicylic AcidsSingle-Blind MethodAzathioprineHodgkin DiseaseRandom AllocationAnalysis of VariancePsychiatric Status Rating ScalesAntidepressive Agents, Second-GenerationAdrenal Cortex HormonesHealth Maintenance OrganizationsCitalopramSulfasalazineDrug EvaluationDelayed-Action PreparationsTreatment FailureSerotonin Uptake InhibitorsWegener GranulomatosisMelphalanAntibodies, Monoclonal, HumanizedPiperazinesMethadoneChronic DiseaseLeukemia, Myelogenous, Chronic, BCR-ABL PositivePain MeasurementPituitary ACTH HypersecretionSertralineLeukocyte Count